With 0.78 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.97 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.875 whereas the lowest price it dropped to was $1.82. The 52-week range on DRRX shows that it touched its highest point at $2.64 and its lowest point at $0.48 during that stretch. It currently has a 1-year price target of $2.50. Beta for the stock currently stands at 0.93.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DRRX was up-trending over the past week, with a rise of 236.53%, but this was up by 178.99% over a month. Three-month performance surged to 211.04% while six-month performance rose 143.14%. The stock gained 148.00% in the past year, while it has gained 14.11% so far this year. A look at the trailing 12-month EPS for DRRX yields -0.51 with Next year EPS estimates of -0.70. For the next quarter, that number is -0.13. This implies an EPS growth rate of -164.00% for this year and -6.06% for next year.
Float and Shares Shorts:
At present, 31.04 million DRRX shares are outstanding with a float of 27.70 million shares on hand for trading. On 2025-07-15, short shares totaled 0.76 million, which was 246.00000999999997 higher than short shares on 1749772800. In addition to Dr. James E. Brown D.V.M. as the firm’s Co-Founder, CEO, President & Director, Mr. Timothy M. Papp M.B.A. serves as its CFO & Secretary.
Institutional Ownership:
Through their ownership of 0.22341 of DRRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, DRRX reported revenue of $321000.0 and operating income of -$4139000.0. The EBITDA in the recently reported quarter was -$3951000.0 and diluted EPS was -$0.13.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DRRX since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DRRX analysts setting a high price target of 2.5 and a low target of 2.5, the average target price over the next 12 months is 2.5. Based on these targets, DRRX could surge 34.41% to reach the target high and rise by 34.41% to reach the target low. Reaching the average price target will result in a growth of 34.41% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.1788 being high and -$0.67547 being low. For DRRX, this leads to a yearly average estimate of -$0.49667.
